Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
19.97
0.19 (0.96%)
At close: Jun 16, 2025, 3:59 PM
19.78
-0.95%
After-hours: Jun 16, 2025, 07:56 PM EDT
0.96% (1D)
| Bid | 14.58 |
| Market Cap | 14.73B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -240.75M |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -58.74 |
| Forward PE | -44.81 |
| Analyst | Buy |
| Ask | 25.48 |
| Volume | 2,059,512 |
| Avg. Volume (20D) | 4,711,503 |
| Open | 20.36 |
| Previous Close | 19.78 |
| Day's Range | 19.74 - 20.59 |
| 52-Week Range | 6.78 - 36.91 |
| Beta | -1.05 |
About SMMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SMMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-30.48%
Summit Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
1 month ago
-36.05%
Summit Therapeutics shares are trading lower. The company's partner Akeso received FDA approval for its PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine. The FDA also approved penpulimab-kcqx as a single agent.
